Clinical Trial Update: Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Extension Protocols MK-0462-022, MK-0462-025, MK-0462-029) [Phase 3]

View source ↗

Summary

Phase 3 long-term exposure study of rizatriptan 5-mg and 10-mg tablets completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine Disorders

Drugs mentioned

• Rizatriptan (Rizatriptan)

Snippet

Sponsor: Organon and Co | Conditions: Migraine Disorders | Phase 3 | Status: COMPLETED | Results posted: 2011-06-10